文献速递胸部肿瘤放疗

优化放疗以改善局部晚期肺癌的临床结局

Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.
PubMed 文献 · Radiat Oncol · 2018-08-13

本研究前瞻性收集2011年11月至2016年8月连续接受加速调强放疗(IMRT)的73例局部晚期肺癌患者资料,评估毒性、局部区域控制(LRC)与总生存(OS)。中位随访44个月,严重肺炎和食管炎(3-4级)分别见于7%和1%的患者,1年、2年LRC分别为76%和62%,1年、2年OS分别为72%和54%;SMART与H-RT两方案间LRC与毒性均无显著差异。

要点

  • 73例局部晚期肺癌接受加速IMRT,中位随访44个月
  • 3-4级肺炎7%、食管炎1%,仅1例4级肺炎
  • 1年、2年LRC为76%、62%,OS为72%、54%

核心结论

  • 局部晚期肺癌的加速IMRT与低毒性和高局部区域控制相关。
  • 作者认为,中度大分割放疗通过缩短总治疗时间,可能有望改善临床结局。

研究设计与样本

  • 2011年11月至2016年8月连续纳入73例接受IMRT的局部晚期肺癌患者。
  • 总剂量66 Gy,采用两种方案:同步调制加速放疗(SMART)(30次×2.2 Gy,共6周)联合或不联合化疗;或对不适合同步化疗者采用中度大分割放疗(H-RT)(24次×2.75 Gy,共4周)。
  • 前瞻性收集食管与肺毒性、LRC和OS数据。

主要发现

  • 中位随访44个月,3-4级严重肺炎见于7%的患者,3-4级食管炎见于1%的患者,仅1例为4级(肺炎)。
  • 1年和2年LRC分别为76%[95%CI:66-87%]和62%[95%CI:49-77%]。
  • 1年和2年OS分别为72%[95%CI:63-83%]和54%[95%CI:43-68%]。
  • 无任何参数与LRC或OS相关;SMART与H-RT之间无差异(P值分别为0.26和0.6),SMART的1年LRC为74%[95%CI:62-86%],H-RT为91%[95%CI:74-100%]。
  • 两种放疗方案的毒性发生率无显著差异。

关键数值与推荐

  • SMART方案:总剂量66 Gy,30次×2.2 Gy,共6周,联合或不联合化疗。
  • H-RT方案:总剂量66 Gy,24次×2.75 Gy,共4周,用于不适合同步化疗的患者。
  • 3-4级肺炎7%、3-4级食管炎1%,仅1例4级肺炎。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to evaluate the toxicity, loco-regional control (LRC) and overall survival (OS) associated with accelerated intensity-modulated radiotherapy (IMRT) for locally advanced lung cancer. METHODS: Seventy-three patients were consecutively treated with IMRT from November 2011 to August 2016. A total dose of 66 Gy was delivered using two different schedules of radiotherapy: simultaneous modulated accelerated radiotherapy (SMART) (30 × 2.2 Gy, across 6 weeks) with or without chemotherapy, or moderate hypofractionated radiotherapy (HRT) (24 × 2.75 Gy, across 4 weeks) in patients unfit to receive concomitant chemotherapy. Data on esophageal and pulmonary toxicities, LRC and OS were prospectively collected. RESULTS: The median follow-up duration was 44 months. Severe pneumonitis and esophagitis (grade 3-4) were observed in 7% and 1% of patients respectively, with only one case of grade 4 (pneumonitis). Overall, the 1-year and 2-year LRCs were 76% [95 confidence interval (CI)%: 66-87%] and 62% [95 CI%: 49-77%] respectively. The 1 and 2-year OS rates were 72% [95% CI: 63-83%] and 54% [95 CI%: 43-68%] respectively. None parameters were correlated with LRC or OS. In particular, no difference was observed between patients treated with SMART and H-RT (p = 0.26 and 0.6 respectively), with a 1-year LRC of 74% [95 CI%: 62-86%] for SMART and 91% [95 CI%: 74-100%] for H-RT. No significant differences were observed in the toxicity rates associated with each of the RT schedules. CONCLUSIONS: Accelerated IMRT for locally advanced lung cancer is associated with low toxicities and high LRC. Moderate hypofractionated RT, by decreasing the total treatment time, may be promising in improving clinical outcomes.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jaksic N, Chajon E, Bellec J, et al. Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer. Radiat Oncol. 2018. PMID: 30103774. doi:10.1186/s13014-018-1094-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。